Patient-centred Deprescribing of Psychotropic, Sedative and Anticholinergic Medication in Elderly Patients With Polypharmacy

Summary

The PARTNER study is a multicentre, two-arm, pragmatic cluster-randomised trial evaluating the impact of a focused and patient-centred cooperation between general practitioners (GPs) and community pharmacists (PARTNER intervention) on reductions in the use of psychotropic, sedative and anticholinergic potentially inappropriate medication (PSA-PIM) compared to a control intervention. The PARTNER intervention comprises (1) education for health care professionals, (2) an interprofessional workshop and case conference, (3) a pharmacy visit with brown bag/medication review and patient empowerment, (4) GP practice visit with shared decision making. The control intervention only comprises a pharmacy visit with brown bag review.

Conditions

• Deprescriptions
• Antidepressive Agents
• Antipsychotic Agents
• Analgesics, Opioid
• Hypnotics and Sedatives
• Cholinergic Antagonists

Interventions

BEHAVIORAL

PARTNER intervention

The PARTNER intervention includes the following components: 1. Education for health care professionals A) written manual on deprescribing PSA-PIM, which consists of brief information and more detailed explanations; B) access to digital instructional videos/podcasts that address potential problems in deprescribing and provide possible solutions; C) checklist for identification of drug-related problems for pharmacists; D) tapering support tool to facilitate the selection of tapering schemes; E) divisibility list for PSA-PIM to support the implementation of tapering schemes; F) empowerment brochures for patients each focussing on one PSA-PIM subgroup 2. Interprofessional workshop and case conference for GPs and pharmacists 3. Pharmacy visit (brown bag/medication review) including patient empowerment 4. GP practice visit including shared decision making (SDM)

BEHAVIORAL

Control intervention

The control intervention only comprises a pharmacy visit with brown bag review.

Sponsors & Collaborators

• Bielefeld University

  collaborator OTHER

• University of Witten/Herdecke

  collaborator OTHER

• University Hospital Heidelberg

  collaborator OTHER

• University Hospital Regensburg

  collaborator OTHER

• Institute for Applied Quality Improvement and Research in Health Care

  collaborator UNKNOWN

• Techniker Krankenkasse

  collaborator OTHER

• Federal Joint Committee

  collaborator OTHER_GOV

• Ludwig-Maximilians - University of Munich

  lead OTHER

Principal Investigators

• Tobias Dreischulte, Prof. Dr. · Institute of General Practice and Family Medicine, University Hospital, LMU Munich, Munich, Germany

Study Design

Allocation

RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-03-25

Primary Completion

2026-04-30

Completion

2026-10-31

Countries

• Germany

Study Locations